The data obtained from prior clinical investigations conducted on individuals diagnosed with POF [29, 35] and POR [20], as well as Phase I and II of the current study [36], consistently demonstrated that the intraovarian injection of MenSC led to a significant elevation in the level of serum AMH and AFC when compared to pre-treatment levels. This evidence concerns the gene AMH and premature menopause.